A HER2 FISH test tells you whether the HER2 gene in your tumor cells has been amplified, meaning extra copies of the gene are present, which drives the cancer to grow more aggressively. The result lands in one of three categories: positive (amplified), negative (not amplified), or equivocal (borderline). Each category has a direct bearing on whether you’re a candidate for HER2-targeted therapies like trastuzumab. But the numbers on your pathology report can look intimidating, and the path from result to treatment decision isn’t always straightforward, particularly when your result falls in one of the gray zones that have kept pathologists debating for years.
What FISH Actually Measures
FISH stands for fluorescence in situ hybridization. It works by applying fluorescent probes directly to thin slices of your tumor tissue on a glass slide. One probe binds to the HER2 gene on chromosome 17, and in a dual-probe test, a second probe binds to the centromere region of chromosome 17 (called CEP17), which serves as a reference point. A pathologist or technologist then counts the glowing signals under a fluorescence microscope. In a normal cell, you’d see about two HER2 signals and two CEP17 signals. In an amplified cell, the HER2 signals vastly outnumber the reference signals.
FISH is considered a highly sensitive and precise method for determining HER2 gene amplification, and it’s one of two FDA-approved approaches alongside immunohistochemistry (IHC).1PubMed Central. Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER 2 /Neu Gene in Kurdish Patients with Breast Cancer in Western Iran While IHC measures how much HER2 protein is present on the cell surface, FISH goes deeper and looks at the gene itself inside the nucleus. The two tests answer slightly different questions, and they don’t always agree.2Clinical Breast Cancer. Frequency of HER2 Immunohistochemistry and In Situ Hybridization Discordance in Breast Cancer
Reading the Numbers on Your Report
Your FISH report will typically include two key numbers: the average HER2 gene copy number per cell and, if a dual-probe test was used, the HER2/CEP17 ratio. The ratio is calculated by dividing the average number of HER2 signals by the average number of CEP17 signals across a set of counted cells (usually at least 20). These numbers determine which of three result categories your tumor falls into.
Under the current guidelines from the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP), a dual-probe FISH result is positive when the HER2/CEP17 ratio is 2.0 or higher and the average HER2 copy number is 4.0 or higher per cell. It’s also considered positive if the ratio is below 2.0 but the average HER2 copy number reaches 6.0 or above, and in rare situations when the ratio is 2.0 or higher with a copy number below 4.0.3OncLive. New ASCO/CAP Guideline Enhances HER2 Testing in Breast Cancer
A result is negative when the ratio is below 2.0 and the average HER2 copy number is below 4.0. If your lab used a single-probe test (no CEP17 reference), negative means the HER2 copy number is below 4.0.
The third possibility is equivocal, which falls in between. On a dual-probe test, this means a ratio below 2.0 with an average HER2 copy number between 4.0 and 5.99. On a single-probe test, it’s a copy number in that same 4.0 to 5.99 range. An equivocal result doesn’t mean cancer is or isn’t HER2-driven. It means the test couldn’t give a definitive answer, and further steps are needed.
What Happens When Your Result Is Equivocal
An equivocal FISH result can be unsettling, but it’s not uncommon. Current guidelines generally classify equivocal results as HER2-negative unless IHC shows strong protein overexpression (scored 3+).4PubMed Central. Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline In practice, this means your oncologist will look at both your FISH numbers and your IHC score together.
Equivocal results can also trigger repeat testing. Research suggests that biopsies producing certain borderline FISH patterns (specifically group 2 and group 4 results in the ASCO/CAP classification system) should ideally be retested on the surgically removed specimen rather than relying solely on the small biopsy sample.5PubMed. Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision A biopsy captures only a tiny fragment of the tumor, and the full excision specimen can sometimes paint a clearer picture.
Alternative FISH testing using different reference probes on chromosome 17 has also been explored for equivocal cases. One study of 100 equivocal tumors found that swapping the standard CEP17 probe for alternative control sites on chromosome 17 could reclassify a substantial number of cases as amplified, though the best alternative probe to use remains debated.6JAMA Oncology. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines Despite the availability of these alternative results, relatively few patients in that study ended up receiving HER2-targeted treatment, suggesting that clinical adoption of alternative probe strategies has been slow.7PubMed Central. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Why FISH and IHC Sometimes Disagree
You might receive an IHC score that doesn’t seem to match your FISH result. IHC measures the amount of HER2 protein sitting on the surface of tumor cells, while FISH measures whether the gene itself has been copied too many times. Most of the time, gene amplification drives protein overexpression, so the two tests agree. But not always. Variable discordance between IHC and FISH has been documented.2Clinical Breast Cancer. Frequency of HER2 Immunohistochemistry and In Situ Hybridization Discordance in Breast Cancer
This is one reason why the testing algorithm works in steps. IHC is typically performed first because it’s easier and cheaper to run. If IHC gives a clear-cut result (0, 1+, or 3+), the answer is usually settled. When IHC comes back as 2+ (equivocal), reflex FISH testing is the standard next step to resolve the ambiguity. Even cases scored 1+ by IHC, which are typically classified as negative, can occasionally harbor HER2 amplification on FISH. One study found that about 15% of IHC 1+ invasive breast cancers with unfavorable characteristics showed HER2 amplification when FISH was performed.8PubMed Central. FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics Findings like these highlight why the two tests complement each other rather than being interchangeable.
Technical Pitfalls That Complicate Interpretation
Two biological phenomena can make FISH results harder to interpret, and both are worth understanding if your result is borderline.
The first is chromosome 17 polysomy, which means your tumor cells carry extra copies of the entire chromosome 17, not just extra copies of the HER2 gene. Because the CEP17 reference probe sits on that same chromosome, extra whole chromosomes inflate both the HER2 and CEP17 signal counts. The ratio can then look normal even though the absolute HER2 copy number is elevated. Research has identified polysomy 17 as a substantial cause of equivocal FISH results.9PubMed Central. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients Making matters more complex, what labs call “polysomy 17” may not always reflect true gain of the entire chromosome. Studies using more detailed genetic analysis have found that extra CEP17 signals often result from broader aneuploidy (gains across multiple chromosomes) rather than isolated duplication of chromosome 17 alone.10Scientific Reports. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study
The second complicating factor is genetic heterogeneity, where different areas within the same tumor have different HER2 gene copy numbers. Some clusters of cells may be amplified while neighboring clusters are not. About 15% of breast cancer patients show this kind of HER2 heterogeneity, and it’s a meaningful contributor to equivocal FISH results.11PubMed. Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance When only 20 or 40 cells are counted (as is typical for FISH), which region of the tumor gets sampled can influence the final number substantially. This is another reason why equivocal or borderline biopsy results sometimes get retested on the larger surgical specimen.
How the Result Affects Your Treatment
HER2 amplification occurs in roughly 12% to 25% of breast cancers and a similar proportion of gastric and gastroesophageal cancers.2Clinical Breast Cancer. Frequency of HER2 Immunohistochemistry and In Situ Hybridization Discordance in Breast Cancer12PubMed Central. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications A positive FISH result makes you eligible for HER2-targeted treatments. These drugs, which include trastuzumab and newer agents, work by blocking the overactive HER2 signaling pathway that drives tumor growth. A negative result means HER2-targeted therapy is unlikely to help, and your treatment plan will be built around other options.
An interesting nuance is whether the degree of amplification matters once you’re in the positive category. One large analysis from the HERA trial found no significant relationship between the HER2 FISH ratio or copy number and how much benefit patients got from trastuzumab.13PubMed Central. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial In other words, a ratio of 3.0 didn’t predict a different benefit than a ratio of 8.0 in that dataset. However, other research has found the opposite at extreme levels: tumors with very high FISH ratios (above 8) and very high copy numbers (above 12) actually showed worse outcomes on standard trastuzumab-containing chemotherapy.14PLOS ONE. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy The clinical significance of this finding is still being worked out, but it suggests that very highly amplified tumors might need more intensive or different treatment strategies than standard regimens provide.
HER2-Low and Why It Matters Now
Until recently, HER2 status was treated as a binary: positive or negative. That framework has shifted with the recognition of a “HER2-low” category, which includes tumors scored IHC 1+ or IHC 2+ with a negative FISH result. These tumors don’t have enough HER2 to qualify for traditional HER2-targeted drugs like trastuzumab alone, but they do express some HER2 protein on their surface.
This distinction became clinically meaningful with the approval of antibody-drug conjugates designed to work even at lower levels of HER2 expression. Because these newer drugs deliver a chemotherapy payload directly to any cell with at least a small amount of HER2 on its surface, tumors that were previously lumped into the “negative” bucket are now potentially treatable. One study examining the spectrum of low HER2 expression found that among 112 patients originally scored in the HER2-negative range, rescoring by breast pathologists identified the majority as HER2 1+ (about 55%), with the rest divided between very low expression and truly absent HER2.15Hindawi / The Breast Journal. Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation
For you as a patient, this means a FISH-negative result doesn’t automatically close the door on HER2-related treatments anymore. Your IHC score now carries additional importance. If your IHC is 1+ or 2+ (with negative FISH), you may be eligible for newer antibody-drug conjugates that your oncologist can discuss. If your IHC is truly 0 with no detectable protein, those drugs are less likely to be offered. The precision of how pathologists score IHC at the low end has become more consequential than it used to be.
Testing Differences in Gastric and Gastroesophageal Cancers
If your HER2 FISH test was for a stomach or gastroesophageal junction cancer rather than breast cancer, the interpretation framework has some important differences. HER2 protein expression in gastric tumors tends to be more patchy and heterogeneous than in breast tumors, partly because of the different tissue architecture of the stomach lining. The IHC scoring criteria are adapted accordingly: gastric cancers allow incomplete membrane staining to still count toward a positive score, whereas breast cancer scoring requires complete membrane staining.16PubMed Central. HER2 testing in gastric cancer: An update FISH cutoffs for gene amplification remain similar, but the greater heterogeneity in gastric tumors means sampling issues are even more of a concern. Testing on biopsy fragments from an endoscopy captures only a tiny portion of what can be a large, spatially varied tumor.
Understanding Your Pathology Report
If you’ve stared at your pathology report and felt lost, you’re far from alone. Research has shown that patient comprehension of common pathology terminology is poor across the board, and assumptions that higher education or medical exposure improves understanding are often wrong.17PubMed. Patient comprehension of breast pathology report terminology: The need for patient-centered resources With many health systems now required to release test results to patients electronically as soon as they’re available, you may see your FISH result before your oncologist has had a chance to explain it. That waiting period between receiving a report and your next appointment can be anxiety-inducing.
A few practical things to keep in mind when reading your report:
- Look for the final interpretation line. Somewhere in the report, the pathologist will state whether HER2 is amplified, not amplified, or equivocal. The raw numbers above that line are the data used to reach that conclusion.
- Dual-probe vs. single-probe. If you see both a ratio and a copy number, a dual-probe test was used. If only a copy number appears, it was a single-probe test. Both are valid, but dual-probe is more common.
- Group classifications. Some reports reference ASCO/CAP groups 1 through 5, which correspond to different combinations of ratio and copy number. Group 1 is clearly positive, group 5 is clearly negative, and groups 2 through 4 are the borderline zones where additional workup may be needed.
- Don’t panic over an equivocal result. It doesn’t mean something is wrong with the test or that your cancer is harder to treat. It simply means the numbers landed in a zone where a definitive call can’t be made yet, and your team will pursue next steps.
Emerging Approaches to HER2 Assessment
FISH has been a workhorse test for HER2 status since the late 1990s, but the technology around it continues to evolve. One active area of development is artificial intelligence-assisted counting. Manually counting fluorescent signals under a microscope is time-consuming and subject to some degree of observer variation. A deep learning model trained on FISH images was able to classify tumors into the five ASCO/CAP groups with about 85% accuracy compared to manual counting.18Scientific Reports. Deep learning to automatically evaluate HER2 gene amplification status from fluorescence in situ hybridization images That’s promising but still leaves about one in seven cases misclassified, so human oversight remains essential. As these tools mature, they could help standardize results across laboratories and reduce turnaround time.
Another developing approach is liquid biopsy, which tests for HER2 gene amplification in fragments of tumor DNA or circulating tumor cells found in a blood sample rather than in surgically obtained tissue. Early results suggest the method picks up HER2 amplification reliably when a tumor is strongly positive but has more limited sensitivity overall. One study comparing digital PCR in blood plasma against tissue-based IHC/FISH in advanced breast cancer patients found a sensitivity of about 44% and a specificity of about 84%.19PubMed Central. Liquid Biopsy and Tissue Biopsy Comparison with Digital PCR and IHC/FISH for HER2 Amplification Detection in Breast Cancer Patients That means the blood test missed more than half of tissue-confirmed HER2-positive cases, making it unsuitable as a standalone replacement for FISH at this stage. However, circulating tumor cell analysis has shown intriguing results in small studies: one pilot found 100% concordance with tissue-based HER2 status in patients with strongly HER2-positive tumors, and it even detected HER2 amplification in a few patients whose needle biopsies had missed it.20Journal of Clinical Oncology. ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer For now, tissue FISH remains the standard, but liquid biopsy could eventually play a role in monitoring HER2 status over time or catching changes that happen after the original biopsy was taken.
When Results Change Over Time
HER2 status isn’t necessarily permanent. When breast cancer recurs or metastasizes, the HER2 status of the new lesion can differ from the original tumor. This is sometimes called discordance between primary and metastatic disease. The reasons are still being studied but likely involve tumor evolution under treatment pressure, as well as the genetic heterogeneity discussed earlier. If some cells in the original tumor were HER2-amplified while others were not, a metastasis that grows from the non-amplified population will test negative.
This is why many oncologists recommend retesting HER2 when cancer recurs at a new site. A patient originally classified as HER2-negative could turn out to be HER2-positive in a metastasis, opening up treatment options that weren’t relevant before. The reverse is also possible. In the HER2-low era, even small shifts in expression level between primary and metastatic tumors can affect eligibility for antibody-drug conjugates.
Tissue handling and laboratory protocols can also affect results, though this is less about the biology changing and more about the test’s sensitivity to preanalytical variables. How long tissue sits in fixative, what type of fixative is used, and how the tissue is processed can all influence signal quality. Labs that perform FISH testing follow standardized quality control protocols to minimize these effects, but no assay is immune to them.